Nov. 18 (UPI) -- Two fairly new medications for heart failure have become staples for those who receive Medicare benefits and are "cost-effective" options, an analysis published Monday in the journal JAMA Cardiology has found.
The study sought to evaluate national patterns of use for sacubitril/valsartan -- marketed as Entresto and manufactured by Novartis -- and ivabradine -- marketed as Corlanor and manufactured by Amgen -- and associated spending on the two drugs within Medicare Part D. Both drugs were approved for the treatment of heart failure with reduced ejection fraction by the U.S. Food and Drug Administration in 2015.